Jeffery Scott Magnuson

Jeffery Scott Magnuson

Auto-generated profile, based on publicly available information

Jeffery Scott Magnuson

Department of Otolaryngology—Head and Neck Surgery AdventHealth Orlando Orlando Florida USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
JHJohn C Hardman
John C Hardman
FHF Chris Holsinger
F Chris Holsinger
GBGrainne C Brady
Grainne C Brady
ABAvinash Beharry
Avinash Beharry
ABAlec T Bonifer
Alec T Bonifer
VPVinidh Paleri
Vinidh Paleri
Background: Transoral robotic surgery (TORS) is an emerging minimally invasive surgical treatment for residual, recurrent, and new primary head and neck cancers in previously irradiated fields, with limited evidence for its oncological effectiveness. Methods: A retrospective observational cohort study of consecutive cases performed in 16 high-volume international centers before August 2018 was conducted (registered at clinicaltrials.gov [NCT04673929] as the RECUT study). Overall survival (OS), disease-free survival, disease-specific survivals (DSS), and local control (LC) were calculated using Kaplan-Meier estimates, with subgroups compared using log-rank tests and Cox proportional hazards modeling for multivariable analysis. Maximally selected rank statistics determined the cut point for closest surgical resection margin based on LC. Results: Data for 278 eligible patients were analyzed, with median follow-up of 38.5 months. Two-year and 5-year outcomes were 69.0% and 62.2% for LC, 71.8% and 49.8% for OS, 47.2% and 35.7% for disease-free survival, and 78.7% and 59.1% for disease-specific survivals. The most discriminating margin cut point was 1.0 mm; the 2-year LC was 80.9% above and 54.2% below or equal to 1.0 mm. Increasing age, current smoking, primary tumor classification, and narrow surgical margins (≤1.0 mm) were statistically significantly associated with lower OS. Hemorrhage with return to theater was seen in 8.1% (n = 22 of 272), and 30-day mortality was 1.8% (n = 5 of 272). At 1 year, 10.8% (n = 21 of 195) used tracheostomies, 33.8% (n = 66 of 195) used gastrostomies, and 66.3% (n = 53 of 80) had maintained or improved normalcy of diet scores. Conclusions: Data from international centers show TORS to treat head and neck cancers in previously irradiated fields yields favorable outcomes for LC and survival. Where feasible, TORS should be considered the preferred surgical treatment in the salvage setting.

31 July 2009 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
DSDawn B. Sharp
Dawn B. Sharp
JNJohn R. Newman
John R. Newman
JMJ. Scott Magnuson
J. Scott Magnuson

7 February 2025 in Head & Neck
Verified
Journal Article
Closed access
ACAndrea Costantino
Andrea Costantino
BHBruce Haughey
Bruce Haughey
JZJianbin Zhu
Jianbin Zhu
UAUthman Alamoudi
Uthman Alamoudi
JMJ. Scott Magnuson
J. Scott Magnuson

23 May 2024 in Oral Oncology
Verified
Journal Article
Closed access
ACAndrea Costantino
Andrea Costantino
BHBruce Haughey
Bruce Haughey
JZJianbin Zhu
Jianbin Zhu
TMTarek Mekhail
Tarek Mekhail
SKShravan Kandula
Shravan Kandula
JMJeffery Scott Magnuson
Jeffery Scott Magnuson

30 July 2025 in The Laryngoscope
Verified
Journal Article
Closed access
ACAndrea Costantino
Andrea Costantino
JHJack Hyler
Jack Hyler
UAUthman Alamoudi
Uthman Alamoudi
FMFawaz Makki
Fawaz Makki
ADAaron Domack
Aaron Domack
JMJ. Scott Magnuson
J. Scott Magnuson

18 September 2024 in The Laryngoscope
Verified
Journal Article
Closed access
ACAndrea Costantino
Andrea Costantino
JMJeffery Scott Magnuson
Jeffery Scott Magnuson
UAUthman Alamoudi
Uthman Alamoudi
BHBruce Haughey
Bruce Haughey